Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal
4 years ago
R&D
The antibody discovery team at Twist bets on mouse model player in a boost to its portfolio
4 years ago
Discovery
Xencor says goodbye to its former lead drug, selling all rights to Lonnie Moulder's new startup
4 years ago
Two of China's top PD-(L)1 players team up on CTLA-4 in $200M deal
4 years ago
China
Joan Perelló set out 17 years ago to develop a drug. And today he's being rewarded with a $424M biotech buyout
4 years ago
Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout
4 years ago
Gilead goes all in on its Arcus alliance, paying $725M cash for rights to a slate of cancer drugs. And there's no room for failure
4 years ago
Cell/Gene Tx
Sanofi inks major AI deal to improve clinical development odds with $270M cash investment
4 years ago
AI
Ahead of expected EU objections, Illumina defends Grail acquisition
4 years ago
Pharma
In wake of PhII flop, Roche walks away from $350M Covid-19 antiviral pact
4 years ago
Coronavirus
A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors
4 years ago
Eye disease specialists venture into M&A with a buyout deal worth up to $126M
4 years ago
J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division
4 years ago
Too much iron? Pharmacosmos is betting $225M on a new potential solution for that
4 years ago
Months after a Merck spinout, Organon continues its string of deals with a $954M buyout package
4 years ago
R&D
Genentech teams with little Novome on IBD research, looking to colonized bacteria after a severe setback
4 years ago
Pfizer wagers $1.2B on Biohaven's lead migraine drug — and picks up a next-gen candidate — as marketing wars heat up
4 years ago
J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'
4 years ago
China's Zai Lab spins 2 more licensing deals, including a sudden dive into neuroscience
4 years ago
China
Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal
4 years ago
R&D
Blackstone doubles down on cell therapy, pouring life (and a lot of cash) into a once hot biotech
4 years ago
Cell/Gene Tx
Fresh off corporate split, bluebird bio plots new hybrid headquarters at Somerville's Assembly Row
4 years ago
People
PlateletBio announces $75.5M Series B to extend autoimmune cell therapy
4 years ago
R&D
More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward
4 years ago
R&D
First page
Previous page
66
67
68
69
70
71
72
Next page
Last page